4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4 Lenvatinib Mesylate Intermediate Purity >98.0% (HPLC)
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib; 1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Chemical Name | 4-Amino-3-Chlorophenol Hydrochloride |
Synonyms | 2-Chloro-4-Hydroxyaniline Hydrochloride |
CAS Number | 618-89-3 |
CAT Number | RF-PI1969 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C6H6ClNO·HCl |
Molecular Weight | 180.03 |
Melting Point | 254.0~256.0℃(dec.)(lit.) |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | Brown Solid Powder |
Purity / Analysis Method | >98.0% (HPLC) |
Purity / Analysis Method | 97.5~102.5% (Titration by AgNO3) |
Loss on Drying | <0.50% |
Residue on Ignition | <0.30% |
Total Impurities | <2.00% |
Infrared Spectrum | Conforms to Structure |
Proton NMR Spectrum | Conforms to Structure |
Test Standard | Enterprise Standard |
Usage | Intermediate of Lenvatinib Mesylate (CAS: 857890-39-2) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
4-Amino-3-Chlorophenol Hydrochloride (CAS: 52671-64-4) is an intermediate of Lenvatinib Mesylate (CAS: 857890-39-2). Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. Lenvatinib is used for the treatment of differentiated thyroid cancer that is either locally recurrent ormetastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine).LENVATINIB is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat thyroid cancer and kidney cancer. Compare kinase inhibitors. Lenvatinib is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively.